阿帕替尼治疗老年性胃癌的安全性分析
|
摘要
目的:探讨阿帕替尼治疗老年性胃癌的临床疗效及不良反应,以期为老年性胃癌的临床诊治提供参考依据。方法:选择某院收治的32例老年性胃癌患者,随机分为观察组和对照组,每组各16例,对照组给予阿帕替尼模拟片治疗,观察组给予阿帕替尼治疗。比较2组患者的临床疗效,并观察阿帕替尼药物治疗的不良反应发生率。结果:观察组患者部分缓解(PR)、病情稳定(SD)、病情进展(PD)及疾病控制率(DCR)均优于对照组,差异有统计学意义(P<0.05);阿帕替尼的不良反应主要有高血压、蛋白尿、骨髓抑制,其中高血压的发生率为50.0%,骨髓抑制的发生率为43.8%,蛋白尿的发生率为37.5%。结论:阿帕替尼可有效控制老年性胃癌病情,不良反应可耐受,值得临床推广应用。
Objective:To analyze the clinical efficacy and adverse reactions of apatinib in treatment of senile gastric cancer so as to provide reference for clinical diagnosis and treatment.Methods:32 patients with senile gastric cancer admitted to hospital were randomly divided into two groups,each with 16 cases.The 16 patients in the control group were treated with simulated tablets of apatinib,while those in the observation group were treated with apatinib.The clinical efficacy of the two groups of patients was compared and the incidence of adverse reactions treated with apatinib was observed.Results:The PR,SD,PD and DCR of the observation group were better than those of the control group,the difference being statistically significant(P<0.05).The adverse reactions of apatinib mainly include hypertension, proteinuria and myelosuppression(50.0%, 43.8%, 37.5% respectively).Conclusion:Apatinib can effectively control the condition of senile gastric cancer, and the adverse reactions can be tolerated. It is worthy of clinical application.
Objective:To analyze the clinical efficacy and adverse reactions of apatinib in treatment of senile gastric cancer so as to provide reference for clinical diagnosis and treatment.Methods:32 patients with senile gastric cancer admitted to hospital were randomly divided into two groups,each with 16 cases.The 16 patients in the control group were treated with simulated tablets of apatinib,while those in the observation group were treated with apatinib.The clinical efficacy of the two groups of patients was compared and the incidence of adverse reactions treated with apatinib was observed.Results:The PR,SD,PD and DCR of the observation group were better than those of the control group,the difference being statistically significant(P<0.05).The adverse reactions of apatinib mainly include hypertension, proteinuria and myelosuppression(50.0%, 43.8%, 37.5% respectively).Conclusion:Apatinib can effectively control the condition of senile gastric cancer, and the adverse reactions can be tolerated. It is worthy of clinical application.
引文
[1]陈万青,郑荣寿,曾红梅,等. 2011年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2015,25(1):1-10.
[2]胡姗姗,向梅,卢萍,等.阿帕替尼联合替吉奥治疗老年一线晚期胃癌患者的临床效果分析[J].养生保健指南,2016(36):33.
[3]段洪瑞,宋岩,姜晓艳.阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌的疗效观察[J].中国实用医药,2017,12(28):155-157.
[4] RAVAUD A,SIRE M. Arterial hypertension and clinical benefit of sunitinib,sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer[J]. Ann Oncol,2009,20(5):966-967.
[5]郎丰平,赵毓毅,范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].实用癌症杂志,2017,32(6):996-998.
[6] CHENG H,SUN A,GUO Q,et al. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population:a systematic review and meta-analysis[J]. Drug Des Devel Ther,2018,12:2173-2183.
[7] RUIXUAN G,JIN L. Apatinib for the treatment of gastric cancer[J]. Expert Opin Pharmacother,2015,16(1):117-122.
[8] CHEN J,WANG J. Efficacy and safety assessment of apatinib in patients with advanced gastric cancer:a meta-analysis[J]. Oncotargets&Therapy,2018,11:4149-4158.
[9]秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015(9):841-847.
[10]樊翠珍,张晓静,初玉平,等.阿帕替尼治疗化疗失败的进展期胃癌的疗效及安全性[J].肿瘤,2018,38(4):356-361.
[11] LI J,QIN S,XU J,et al. O-0029 PHASE III STUDY OF APATINIB IN ADVANCED GASTRIC CANCER:A RANDOMIZED,DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL[J]. Journal of Clinical Oncology,2014,25(suppl 2):117.
[2]胡姗姗,向梅,卢萍,等.阿帕替尼联合替吉奥治疗老年一线晚期胃癌患者的临床效果分析[J].养生保健指南,2016(36):33.
[3]段洪瑞,宋岩,姜晓艳.阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌的疗效观察[J].中国实用医药,2017,12(28):155-157.
[4] RAVAUD A,SIRE M. Arterial hypertension and clinical benefit of sunitinib,sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer[J]. Ann Oncol,2009,20(5):966-967.
[5]郎丰平,赵毓毅,范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].实用癌症杂志,2017,32(6):996-998.
[6] CHENG H,SUN A,GUO Q,et al. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population:a systematic review and meta-analysis[J]. Drug Des Devel Ther,2018,12:2173-2183.
[7] RUIXUAN G,JIN L. Apatinib for the treatment of gastric cancer[J]. Expert Opin Pharmacother,2015,16(1):117-122.
[8] CHEN J,WANG J. Efficacy and safety assessment of apatinib in patients with advanced gastric cancer:a meta-analysis[J]. Oncotargets&Therapy,2018,11:4149-4158.
[9]秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015(9):841-847.
[10]樊翠珍,张晓静,初玉平,等.阿帕替尼治疗化疗失败的进展期胃癌的疗效及安全性[J].肿瘤,2018,38(4):356-361.
[11] LI J,QIN S,XU J,et al. O-0029 PHASE III STUDY OF APATINIB IN ADVANCED GASTRIC CANCER:A RANDOMIZED,DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL[J]. Journal of Clinical Oncology,2014,25(suppl 2):117.